GAIA-102 for relapsed or hard-to-treat childhood cancers
Part of Cancer clinical trials.
This Phase 1 study tests GAIA-102 in children and young adults whose cancer has returned or not responded to standard treatments. It aims to see if the treatment is safe and whether it may shrink tumors in certain pediatric solid cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be confirmed by biopsy as one of the listed types, such as neuroblastoma or certain other solid tumors
- If you have neuroblastoma: it must have relapsed or resisted at least two prior treatment regimens (or, for some groups, you finished dinutuximab but still have tumor)
- Your age must be 1 to 24 years old when you sign consent
- You must not have spread to the brain (no brain metastases) and not have cancerous meningitis
- You should be able to carry out daily activities at a moderate level (performance score requirements must be met)
- You must not have had an allogeneic stem cell transplant and must not have a currently active autoimmune disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug called IR-101 for children with high-risk neuroblastoma that has come back or isn't responding to treatment. It aims to see if the drug is safe and can help shrink tumors that show up on a MIBG scan.
This Phase 1 study tests lab-made donor immune cells (gamma delta T cells) plus chemotherapy to treat neuroblastoma or osteosarcoma that has come back or hasn’t responded to standard treatment. It’s designed to find a safe way to give this treatment and to see how well it might work.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This Phase 1/2 trial tests a study treatment for children and young adults under 22 whose brain glioma has come back or isn’t responding to prior treatment. It’s designed to see whether the treatment is safe and effective for shrinking tumors in this situation.
This early-phase trial tests an immune-cell treatment made from the child’s own cells, designed to attack neuroblastoma. It aims to help children whose cancer has come back or did not respond to standard treatment.
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
Hear when a new Refractory/Relapse Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.